Company & Sponsor Intelligence
Pfizer
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials2
Recruiting0
Completed2
Countries2
Therapeutic footprint
alzheimersunclassified
Indexed studies
NCT01654250NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD)
adhd · United StatesPHASE3
adhd · United StatesPHASE3
NCT007387386-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)
anxiety · United StatesPHASE3
anxiety · United StatesPHASE3
NCT00455000A Phase I, Single IV Dose Of PF-04360365 In Adults With Mild To Moderate Alzheimer's Disease
alzheimers · AustraliaPHASE1
alzheimers · AustraliaPHASE1
NCT01285518Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes
unclassified · United StatesPHASE1
unclassified · United StatesPHASE1
Intelligence layer updated: 2026-06-10 02:57:56.223123+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →